In melanoma cells, cleavage of caspase-3 and PARP were reported when cells were treated with the Mcl-1 inhibitor A-1210477 in combination with ABT-263 [74], and in activity assays, activated caspase-3/7 was reported after combined S63845/ABT-263 treatment [55]. The gene discussed is MCL1; the disease is melanoma.